Novo Nordisk target cut by Deutsche Bank despite long-term optimism

Core Viewpoint - Deutsche Bank has reduced its price target for Novo Nordisk by 16% to DKK400, citing revenue challenges, management uncertainty, and clinical trial risks [1]. Group 1: Financial Performance and Projections - The analyst warned of a "double-digit revenue decline" for Novo Nordisk in the current year, although the stock is trading at a "mid-teens price-to-earnings ratio" [2]. - The launch of an oral obesity treatment and potential demand recovery in the second half of the year may support the stock [2]. Group 2: Management and Business Environment - The current management situation is described as fluid, with limited business visibility and a clear downside scenario [3]. - Data from clinical trials of CagriSema, a key obesity treatment candidate, will be critical for future performance [3]. Group 3: Market Reaction - Following the announcement, Novo Nordisk shares fell by 2.4% to DKK307.55 [3]. - Despite the target cut, Deutsche Bank maintained a 'buy' rating on the stock [3].